Instrumenting a Fetal Membrane on a Chip as Emerging Technology for Preterm Birth Research by Gnecco, JS et al.
This is a repository copy of Instrumenting a Fetal Membrane on a Chip as Emerging 
Technology for Preterm Birth Research.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/115194/
Version: Accepted Version
Article:
Gnecco, JS, Anders, AP, Cliffel, D et al. (4 more authors) (2017) Instrumenting a Fetal 
Membrane on a Chip as Emerging Technology for Preterm Birth Research. Current 
Pharmaceutical Design, 23 (40). pp. 6115-6124. ISSN 1381-6128 
https://doi.org/10.2174/1381612823666170825142649
© This is an author produced version of a paper published in Current Pharmaceutical 
Design. Uploaded in accordance with the publisher's self-archiving policy.
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
1Instrumenting a Fetal Membrane on a Chip as Emerging Technology for Preterm Birth Research1
Juan S. Gnecco1,6, Anjali P. Anders2, David Cliffel3, Virginia Pensabene4,  Lisa M. Rogers5, Kevin Osteen1,6,7, and2
David M. Aronoff1,5*3
4
1Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN5
2Division of Neonatology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN6
3Department of Chemistry, Vanderbilt University, Nashville, TN7
4School of Electronic and Electrical Engineering, & School of Medicine, Leeds Institute of Biomedical and Clinical8
Sciences, University of Leeds, Leeds, UK9
5Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN10
6Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, TN11
7VA Tennessee Valley Healthcare System, Nashville, TN12
13
*Corresponding author:14
David M. Aronoff, MD15
1161 21st Avenue South16
A-2200 MCN17
Nashville, TN 37232-258218
Ph: 615-322-897219
Fax: 615-343-616020
d.aronoff@vanderbilt.edu21
22
23
Key words: prematurity, pregnancy, infection, microfluidic, chorioamnionitis, PPROM24
25
2Abstract26
Preterm birth (PTB) is  clinically defined as process of giving birth before 37 weeks of gestation and is  a27
leading cause of death among neonates and children under the age of five. Prematurity remains a critical issue in28
developed countries, yet our understanding of the pathophysiology of PTB remains largely unknown. Among29
pregnancy complications, subclinical infections such as chorioamnionitis (CAM) are implicated in up to 70% of PTB30
cases. Specifically, CAM is characterized by the infection of the fetal membranes that surround the developing fetus31
and extend from the placenta, and is often associated with preterm, premature rupture of the fetal membranes32
(PPROM). The fetal membrane plays a key structural role in maintaining the fetal and maternal compartments of the33
gravid uterus. However, our understanding of the mechanisms of PPROM and the spatio-temporal progress of CAM34
remains vastly unknown. A lack of human-derived models have hindered our understanding of the mechanism that35
govern spontaneous PTB. Thus, in this short review, we discuss the emerging microfabrication technologies,36
specifically, organ-on-chip (OoCs) models, that seek to recapitulate the cellular and molecular context of the37
gestational membranes in vitro. These models show promise to facilitate the investigation of pathologic mechanisms38
that drive these disease conditions by mimicking the interactive contribution of the major cell types that make up the39
microenvironment of the fetal membrane and enable high throughput screening. Herein, we histologically characterize40
the microenvironment of the fetal membrane as a metric for scaling to recapitulate the functional components of the41
human fetal membrane. We review the current OoC models of the gravid uterus and conceptualize an “Instrumented42
Fetal Membrane on a Chip” (IFMOC) design as a prototype for PPROM and CAM research. Lastly, we discuss further43
applications of these OoC models for toxicological or pharmacological screening and personalized medicine. Fetal44
membrane OoCs offer an innovative and valuable platform to explore complex interactions between multiple drug45
types, toxic substances, and/or pathogenic microbes and their potential impacts on pregnancy outcomes. Further work46
will be required by integrating technological and analytical capabilities in order to characterize the fetal membrane47
microenvironment for preterm birth research.48
3Introduction49
Annually, nearly 15 million preterm births (PTB) occur worldwide (1), making prematurity the leading cause of death50
in neonates and the second-leading cause in children under 5 years old (2, 3). While there are many causes of PTB, it51
is most often caused by subclinical infection of the membranes that surround the developing fetus and extend from52
the placenta, a condition referred to as infectious chorioamnionitis (CAM). This usually the result of bacteria53
ascending from the vagina to invade the fetal membranes (Figure 1) (4). The fetal membranes are a critical protective54
barrier during normal pregnancy and are composed of three structural layers, including the fetal-derived amnion and55
chorion and the maternal-derived decidua (5). Despite this relatively simple organ structure, little is known about how56
fetal membranes participate in immune defense or how microbes evade these defenses.57
58
Defining the host-microbial interactions within the fetal membrane at a cellular and molecular level will reveal59
actionable targets for early diagnosis, prevention and treatment of CAM. As many as 70% or more of preterm births60
are associated with CAM, particularly when the delivery occurs before 30 weeks of gestation (6). Babies exposed to61
CAM in utero are at increased risk for neonatal sepsis, necrotizing enterocolitis, bronchopulmonary dysplasia, cerebral62
palsy and retinopathy of prematurity (7). Unfortunately, CAM is often asymptomatic and difficult to diagnose in time63
to prevent maternal and fetal adverse outcomes. Furthermore, subsets of pregnant women with microbial64
contamination of amniotic fluid carry their pregnancy to term, suggesting host factors likely influence the risk for65
CAM-associated PTB (8). Additionally, antibiotic therapies have shown discrepancy between populations of women66
and have failed, for the most part, to prevent preterm birth (9, 10).  A common pregnancy complication that stems67
from CAM and is a major contributor to the burden of PTB is preterm premature rupture of the fetal membranes68
(PPROM). Although fetal membrane rupture is an essential part of the delivery process, PPROM at less than 34 weeks69
of gestation is responsible for approximately 25% of premature births (11). Our limited understanding of the early70
steps involved in disease pathogenesis impedes solutions to this immense problem.71
72
There is a significant deficit in tractable model systems of human fetal membranes. Most studies of human fetal73
membrane immunology employ traditional cell and ex vivo tissue culture models (12, 13), and are limited by either74
loss of the biological context or an inability to maintain ex vivo tissues for prolonged periods. Tissue culture also lacks75
the capability to dissect the roles of individual cell types within the context of a tissue microenvironment. Typically,76
4independent cell and tissue culture experiments are conducted and terminated at discrete time points and do not convey77
the molecular pathways involved throughout the course of infection. This disjointed approach creates challenges for78
understanding the dynamic host-microbial relationship. In addition, these culture systems often rely on relatively large79
culture media volumes employed which may dilute paracrine signals involved in cellular crosstalk. Animal models80
are beneficial for physiologic studies, but the placenta and fetal membranes have tremendous differences in anatomy81
and physiology amongst mammalian species. These biological differences from humans limit progress towards82
translational solutions (14, 15). Thus, there is an essential need to develop robust models of human CAM that can83
eliminate species-specific differences, incorporate all relevant cell subtypes to accelerate research in immunology and84
microbiology (16, 17).85
86
Microfluidic organotypic model systems, commonly referred to as Organ-on-Chip (OoC) technologies, are expected87
to have a major impact on drug discovery, screening, and assessment of efficacy and safety (18, 19). Such 3D platforms88
may recapitulate inter- and intra-cell signaling and the physiological context of tissue dynamics by89
compartmentalizing the major cellular components for quantitative and qualitative analysis (18). Apart from their90
potential role in clinical pharmacology, such OoC models can be used to study the effects of environmental insults91
(e.g., toxins, radiation, or malnutrition) or infections on human health (20). Reproductive tract organotypic culture92
models are emerging to meet this need (21). In this review, we describe existing OoC of the gravid uterus and provide93
conceptual insight into an emerging tool, the instrumented fetal membrane-on-chip (IFMOC), a new model our team94
is developing. An IFMOC could provide a living, continuously perfused model of the fetal membrane that can be95
leveraged to shed new light on many physiological and pathophysiological processes, including host-microbial96
interactions that occur during CAM and PTB. Here, we use PPROM as an example of a gestational membrane disease97
process that can be examined using this OoC model.98
99
100
5Existing organ-on-chip (OoC) models of the gravid uterus101
Advances in biomedical engineering are increasingly deployed in microphysiological models geared toward102
mimicking multiple organs in vitro in  many disciplines including reproductive biology (21). By utilizing microfluidic103
technologies, OoC devices can provide controlled perfusion inside microfluidic structures, which can then refine cell104
and medium volume ratios and emulate bloodstream-like flow (to continuously supply nutrients and remove wastes105
while mimicking hemodynamic forces) (22). One major goal is to hasten the speed and improve the accuracy of106
toxicity testing in preclinical drug development (21), however, such models might also be used to gain new insight107
into tissue level physiological processes and disease pathogenesis (20). Applications of these technologies as108
innovative tools for reproductive research have recently emerged as discussed below.109
110
References cited in this review relevant to OoC models of the gravid female reproductive tract were obtained by111
searching the MEDLINE database for English language articles using PubMed (United States National Library of112
Medicine (Bethesda, MD)) for all years available. The following search terms or combination of terms were used:113
“endometrium”, “embryo”, “microfluidic”, “organ on chip”, “placenta”, “pregnancy”, and “reproductive tract”.114
Additional references were obtained through bibliographies cited in manuscripts. Literature was reviewed through115
December 2016.116
117
OoC models of embryo implantation118
In this review, we focused on the post-implantation embryo; however, microfluidic models of the pre-implantation119
embryo have been developed and reviewed elsewhere (23-25). Although early attempts at modeling embryo120
implantation using a microfluidic 2-chamber device were presented in abstract form in 2007 (24, 26, 27), it was not121
until 2009 that Kimura and colleagues developed a static, 2-chamber OoC capable of culturing a single mouse embryo122
on a bed of endometrial stromal cells (22). Their device consisted of an upper polydimethylsiloxane (PDMS) chip123
with multiple cell trap wells and a lower PDMS chamber with a microchannel for chemical supply along with a124
polyester microporous membrane from a commercially available culture insert plate (22). This approach was believed125
at the time to be the first single embryo co-culture device for the management of mammalian embryos (22). In 2014,126
Chen and collaborators advanced the field for co-culturing a single embryo with a lawn of endometrial stromal cells,127
using a fabricated PDMS dual-chamber device coated with type IV collagen and subjecting the device to a constant128
6media flow (28). This model enhanced the quality of embryo culture by utilizing microfluidic technologies. A more129
recent, but similar approach was taken by Chang et al. to develop a comprehensive stand-alone microfluidic platform,130
“Womb-on-a Chip”, that mimics the microenvironment and incorporates key parameters of embryo implantation,131
including mild biomechanical forces (29). This model used PDMS based microfluidic chambers to directly co-culture132
primary endometrial stromal fibroblasts with murine embryos with the ability to visualize the implantation process in133
real time.134
135
To our knowledge, these devices have not been applied to the clinical problem of PTB, but were developed to address136
the root mechanisms of infertility and improve assisted reproductive technology (ART). However, there is potential137
to use such devices to better understand early events during pre-conception and the establishment of pregnancy that138
may lead preterm birth.139
140
OoC models of the placenta141
The human placenta is an understudied organ that has long been appreciated to play a major role in important142
complications of pregnancy, including prematurity, infection, intrauterine growth restriction, (pre)eclampsia and143
gestational diabetes (30-33). More recently, attention has focused on the placenta for its potential role in the144
developmental origins of health and disease (DOHaD), a paradigm that relates early life exposures (including145
gestational health) to lifespan and disease risk in offspring (34, 35). The possibility that placental pathology could be146
a critical root mechanism for major causes of morbidity and mortality in adults (36, 37), such as cardiovascular disease,147
obesity, diabetes, and neurocognitive problems, creates a new importance for defining normal placental structure and148
function. Knowledge of placental molecular biology lags behind that of other organs; however, this is not surprising,149
since it is not feasible to sample an individual human placenta at multiple time points throughout pregnancy. Thus,150
there is a need for new models of placental biology that can be applied to understanding both normal and disease151
states.152
153
Recently, two groups have published placenta OoC models (38, 39). The placental chip system reported by Lee, et al.154
was developed using a technique known as soft lithography, resulting in a microfluidic system made of two PDMS155
chambers separated by a thin extracellular matrix membrane. An immortalized trophoblast cell line (JEG-3) combined156
7with primary human umbilical vein endothelial cells (HUVEC) were used to represent two of the major non-immune157
cell types of the placenta in the device. These cells were seeded onto the opposite sides of the extracellular matrix158
membrane and cultured under dynamic flow conditions. Confluent layers of trophoblasts and endothelial cells were159
generated in close apposition in order to mimic the human placental maternal-fetal interface (39). Functional validation160
of this system was performed by measuring glucose transport across the trophoblast-endothelial interface over time.161
The permeability of the barrier was analyzed and compared to that obtained from acellular devices and additional162
control groups comprised of either epithelial or endothelial layers alone (39).163
164
The OoC model developed by Blundell, et al., was very similar to the Lee report, utilizing a two-chamber PDMS165
device generated via soft lithography and populated with a primary vascular cell type (human primary placental villous166
endothelial cells (HPVECs)) and a placental choriocarcinoma epithelial cells (BeWo, ATCC), separated by a porous167
membrane coated with extracellular matrix components (38). As in the Lee study (39)(38)(39), the investigators168
demonstrated functionality of the device in terms of permeability, hormone production and nutrient transport (38).169
Both models of the trophoblast-vascular interface represent important advances in microscale modeling of the human170
placenta. However, a limitation of these OoC models was the simplified cellular community structure, lacking immune171
cells and other relevant non-immune cells such as decidual stromal cells. It is anticipated that these types of placental172
OoCs will further advance our understanding of maternal-fetal nutrient and waste transport, drug toxicity,173
immunology/tolerance, and the pathogenesis of infectious diseases as well as other complications of reproduction.174
175
In a recent report, Sticker, et al., developed a multi-chambered microfluidic device that further enhance the176
development of complex in vitro cell cultures for placental research. These models will be essential for developing a177
robust culture system that provides the individual assessment of each cell type (40, 41). Professor Peter Erlt’s group178
fabricated a 4-chamber device using a photosensitive thermoset (OSTEMER 322-40) as a porous membrane and used179
it to establish a compartmentalized tri-culture of human umbilical vein endothelial cells (HUVEC), BeWo cells, and180
adipose tissue-derived human mesenchymal stem cells (adMSCs) (40). These organs-on-chips offer an opportunity to181
enhance the multicellular in vitro models of complex tissues, including the placenta and fetal membranes, and182
demonstrates the increasing complexity of in vitro tissue modeling. Altogether, these models represent the driving183
interest in the development of OoCs of the gravid uterus to better understand maternal-fetal interactions.184
8185
Potential OoC Models of the Fetal Membrane186
Existing models of the human fetal membrane187
Current studies of human fetal membrane immunology employ traditional cell and tissue culture models. Cell culture188
is limited by the loss of the biological context provided by neighboring cells and matrix, while tissue culture is crippled189
by an inability to maintain viability ex vivo for prolonged periods of time (without contamination). To advance fetal190
membrane research, transwell platforms have been implemented to dissect the maternal and fetal polarization of these191
membranes (42-44). In these models, the ex vivo human membrane tissue is used to recreate the membrane of a192
transwell assay and thereby offers the ability to determine differences between the apical (amniotic) and basal193
(choriodeciual) compartments of the fetal membrane tissue. Although this method allows for whole fetal membrane194
cultures in similar anatomical context as would be seen in vivo including unidirectional pathway of an infection, its195
reliance on inclusive human tissue acquisition, short term cultures, as well as intra-sample and donor-to-donor196
variability, impact the reproducibility of results and limit its applications for mechanistic studies.197
198
Tissue culture also lacks the capability to dissect the roles of individual cell types within the context of whole tissue.199
Typically, independent cell and tissue culture experiments are conducted and terminated at discrete time points200
throughout the course of infection. This disjointed approach creates challenges for understanding the dynamic host-201
microbial relationship. In addition, these culture systems suffer from dilutional effects imposed by the relatively large202
culture media volumes employed (16). Animal models have been invaluable tools; however, they are also limited,203
presenting endocrine, anatomical and immunological differences from humans (14, 15). Thus, there is an urgent need204
to develop better human translational CAM models to eliminate species-specific differences and accelerate research205
in immunology and microbiology (16, 17). Development of innovative OoCs of the fetal membrane would provide a206
foundation for robust in vitro human studies that could supplement in vivo animal and ex vivo human studies (Table207
1).208
209
210
211
212
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Table 1. Potential advantages of an instrumented fetal membrane on a chip (IFMOC) device
Creates a highly defined, living model of human fetal membrane that can be maintained for days-to-weeks
The ability to define the contribution(s) of individual cell types to the immunology of intact membranes, facilitating
high-resolution mapping of autocrine and paracrine signaling networks within this compartment
The potential to incorporate transgenic and gene-deficient cell types within the membranes and to define the
contribution of particular genes and gene-networks to human reproductive immunology (and physiology)
The capacity to better model covariates such as fetal sex or race/ethnicity at the tissue level
The ability to incorporate the IFMOC into novel imaging tools and downstream analytics while preserving the
capacity to perform longitudinal studies throughout the course of infection: from colonization to invasion
214
215
The Microenvironment of Fetal Membranes216
Fetal membranes are a deceptively simple tissue structure (5, 45), composed primarily of decidual stromal cells,217
chorionic trophoblasts, fibroblasts (mesenchymal cells), a monolayer of amniotic epithelial cells, resident immune218
cells and a collagen-rich extracellular matrix. While the exact fetal membrane thickness and cell densities are variable219
between individuals, the overall cell ratios and histologic analysis between the somatic cells demonstrate a consistent220
composition (Figure 2). In our models, we have purposely omitted the structural mesenchymal cells for the sake of221
simplicity and focused on the functional reproductive cells. We also summarize the calculated histological222
composition of the fetal membrane and its cellular subtypes (Figure 3a.). These descriptive parameters provide an223
idealized scaling design for OoCs that completely or partially recapitulate the cellular components of the fetal224
membrane. It is important to keep in mind that these approximations do not consider subpopulations within each cell225
type and may change temporally and spatially between each sample.  Immune cells exist within this structure, where226
approximately 35% of immune cells are T lymphocytes, 14% are NK cells, 9% are monocyte/macrophage cells and227
2% are B cells (46, 47). CD68+ Macrophages are therefore the major innate immune phagocyte in uninfected fetal228
membranes (48-51) and make up approximately 9-13% of total cells residing in the fetal membrane (Figure 3a).229
However, how macrophages govern host defense and inflammatory responses is uncertain. An interesting feature of230
fetal membranes is the coexistence of maternal-derived decidual macrophages and fetal-derived macrophages (a.k.a.231
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placental macrophages or Hofbauer cells) (52-55). Although studies have identified epigenetic differences between232
maternal and fetal macrophages isolated from the same gestational tissues (53), we lack knowledge regarding233
functional differences between macrophage subtypes in the context of infection. Animal data suggest that234
macrophages drive PTB in the setting of inflammation or infection but have not determined the contributions of235
maternal and fetal macrophages to this process (56-59). By integrating most of these cells in a tissue-level context that236
recapitulates the dynamic crosstalk of these somatic and immune cells, it may be possible to understand the roles of237
each cell type in the regulation of inflammation, maintaining homeostasis and avoiding CAM.238
239
As noted above, CAM is a major cause of PTB (60), preterm premature rupture of membranes (PPROM) (61), stillbirth240
(62), and neonatal sepsis (63, 64). Bacterial CAM provokes inflammatory responses that trigger early labor (65) and241
contribute to a fetal inflammatory response syndrome (FIRS) (60). Unfortunately, CAM is often clinically silent until242
an adverse event occurs (66). Developing accurate, early diagnostic tests and preventive and/or therapeutic243
interventions requires a better understanding of mechanisms of disease pathogenesis, particularly events occurring244
early during host-microbial interaction. While the above section described published OoC models of the gravid uterus,245
there is not, to our knowledge, a functional OoC of the human fetal membrane. Using OoC technologies it may be246
possible to develop a living fetal membrane model to characterize cellular interactions and response to infections (19).247
Conceptually, a highly defined in vitro model of human fetal membrane that can be maintained for days-to-weeks248
with an ability to define the contribution(s) of individual cell types to the immunology of intact membranes would249
facilitate the high-resolution mapping of autocrine and paracrine signaling networks that occur within this tissue. This250
compartmentalized model would enable both phenotypic and biochemical analytics to characterize fetal membrane251
barrier integrity as a method to study CAM mediated disease conditions (e.g. PPROM).252
253
In order to reduce the burden of intra-sample variability, commercially available cell lines are commonly used as254
displayed by the OoCs described above. Primary cells obtained from donors or patients also can be implemented255
within these models. Depending on the source of cells utilized, fetal membrane OoCs could developed to model either256
healthy or abnormal pregnancies. Primary cells could be employed, for example, from fetal membranes obtained from257
preterm labors or PPROM and used to study disease pathogenesis. Furthermore, induced pluripotent stem cells (iPSCs)258
could be obtained from mother-child pairs, even years postpartum, and differentiated into the unique fetal membrane259
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cell types for use in a membrane OoC. Genetic engineering tools, such as CRISPR/Cas9, can be harnessed to260
manipulate the contribution of specific genes to membrane biology. Thus, an effective fetal membrane OoC model261
might be modified to use diverse cell types gain a deeper insight into disease pathogenesis or to understand normal262
reproductive processes. This ability to incorporate primary cells into OoCs supports both precision and personalized263
medicine initiatives.264
265
Herein, we provide an example of an idealized OoC model of the fetal membrane (Figure 3b.); however, the design266
and complexity of models will certainly be subject to alternative configurations to satisfy the driving experimental267
question. Our team is currently developing an instrumented fetal membrane-on-chip (IFMOC) device to recapitulate268
anatomical, biochemical and reproductive processes of the fetal membrane that physically separates maternal and fetal269
components (Figure 4). We envision that the IFMOC will model important biological variables such as fetal sex270
and/or race/ethnicity at the tissue level and incorporate novel imaging tools and downstream analytics into longitudinal271
studies throughout the course of infection: from colonization to loss of membrane integrity.272
273
Development of a first generation IFMOC274
Deconstructing fetal membranes into component cell types in the highly-controlled environment of the IFMOC will275
provide the capacity to define the contribution of cell-type-specific signaling in response to infection. A major276
advantage of the IFMOC over native ex vivo fetal membranes is the ability to tightly control cell populations to reduce277
intra-sample variability (Figure 4a). Using microfluidics technologies, we can load, perfuse and stimulate each cell278
type separately, and inject, recirculate or sample media from each compartment to maintain short or long-term culture279
experimental designs. We have recently developed a universal dual-chamber microfluidic device using a high-280
resolution porous membrane to establish a model of the non-gravid endometrial perivascular stroma, which has281
provided the technology to establish a prototype of the first generation IFMOC. The microfabrication protocol282
describes a PDMS two-chamber device divided by high-resolution semipermeable resin-based (1002F) transparent283
membranes (67, 68). This membrane allows for both diffusion of molecules and passage of bacteria. It simultaneously284
serves as basal lamina to compartmentalize each cell type.285
286
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As a proof of principle of the applications of this device, our group used primary human umbilical vein endothelial287
cells (HUVECs) and endometrial stromal fibroblasts to model the perivascular stroma of the endometrium (68). Using288
this microfluidic platform, we functionally measured barrier integrity and hormone sensitivity of the stromal289
fibroblasts to undergo the process of decidualization in a long-term culture that mimicked the length and hormonal290
changes associated with an idealized menstrual cycle. These results provide the potential of this microfluidic model291
to maintain long-term cultures, mimics physiological responses to hormones, offers the potential to model endothelial292
(or epithelial barrier function) and ensures sufficient sensitivity of the device to biochemically measure paracrine293
molecules from the conditioned media (68). By applying these microfabrication and engineering technologies to the294
cells that make up the fetal membrane, we can begin to integrate the first generation of the IFMOC to model the295
compartmentalization of chorion/decidua and amniotic components of the fetal membrane in vitro while significantly296
reducing the total volumes required to establish a co-culture. As mentioned, this reduction may provide a stronger297
signaling network between compartmentalized cells and thus a more robust crosstalk. In the first series of experiments,298
we have established co-cultures of amniotic epithelial cells and decidual cells using the two-chamber device (Figure299
4b). Similarly, we have established amniotic epithelial cell co-cultures with trophoblasts (not shown). The goal300
remains to compartmentalize each cell type to assess their individual contribution to fetal membrane homeostasis and301
function, perhaps using existing multi-chambered devices as in the work by Sticker and colleagues (40). We have302
initially focused the IFMOC to identify possible roles of the choriodecidua in regulating amniotic epithelial barrier303
integrity in response to bacterial infections during CAM-induced PPROM. After optimization of co-culture of the304
adherent primary cells inside the IFMOC, (i.e., decidual cells, chorionic trophoblasts, mesenchymal fibroblasts, and305
amniotic epithelial cells) we will introduce macrophages, as a representative leukocyte, to assess the immunological306
interaction in CAM. However, the capability to introduce other key immunological cells (e.g., neutrophils) is feasible307
within this microfluidic platform.308
309
Assessment of response to infection using IFMOC310
To utilize the IFMOC as a qualitative and quantitative tool, we propose introducing electrical sensors or biological311
reporters to assess for markers of alterations in metabolic activity (glucose consumption, extracellular acidification312
and lactate production) and oxidative stress (superoxide generation). As a demonstration of feasibility of this approach,313
we have used a microfluidic multianalyte microphysiometer (MAMP) to assess macrophage metabolic responses to314
13
infection (69). On-chip metabolism can be measured by utilizing screen-printed electrodes for microphysiometry,315
allowing real-time assessment of glucose utilization and lactate production, as above (70, 71). Inflammatory mediators316
and metalloproteinases produced during CAM may lead to PPROM and can be quantified through secretion sampling317
of spent media through direct enzyme linked immunoassay (ELISA) or high throughput proteomics such as protein318
multiplex arrays, as well as fluorescence based biosensors and functional enzymatic activity assays (72, 73). As319
described above, barrier integrity of the amniotic epithelium is important for membrane physiology and quantitative320
models of this component of the fetal membrane will provide insight into the putative pathophysiological mechanisms321
of PPROM. This approach will facilitate our ability to test our sub-hypothesis regarding the contribution of322
macrophages to the pro- and anti-inflammatory balance and effect of inflammation on the integrity of the fetal323
membrane.324
325
326
Discussion327
Maternal-fetal health is a field of research that is difficult to study due to both complex ethical and physiological328
dilemmas, which have undermined our understanding of pregnancy related disease processes including preterm birth.329
Specifically, the lack of translatable and physiological models that recapitulate human conditions hinder both the330
ability to examine the mechanisms behind reproductive disorders, such CAM that result in PTB, and identify331
therapeutic targets. As mentioned above, the fetal membrane plays an integral physiologic function to create a barrier332
and encapsulate the embryo to form a maternal-fetal interface. Under the correct temporal signals, the orchestrated333
rupture of this membrane is a necessary process during term deliveries. However, PPROM is a major contributor to334
prematurity and accounts for approximately 25% (74) of all PTBs. To facilitate our understanding of the335
pathophysiology of these diseases, we must identify the interactive contributions of the major cell types that comprise336
the microenvironment of the fetal membrane. This objective requires more robust, quantitative models that recapitulate337
the human condition. Current models to understand this issue include animal models, human ex vivo tissue approaches,338
and in vitro cultures of human reproductive cells. Emerging approaches, including OoC and microfluidic technologies339
offer innovative technologies to enhance the in vitro modelling of human organs and tissues. In recent years,340
significant  interest has been put forth by several agencies including the Environmental Protection Agency (EPA), the341
Human Placenta Project (National Institutes of Health)(75) and the National Center for Advancing Translational342
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Sciences (NCATS) to develop these organotypic models of the reproductive tract, including the gravid uterus. Thus,343
we introduce the IFMOC as an approach to compartmentalize the cells that form the fetal membrane in order344
understand the immune-endocrine mechanisms behind CAM and PPROM induced preterm birth.345
346
The integration between engineering and reproductive biology promises to provide novel robust models as347
instrumented tools for discovery research and predictive toxicology for environmental chemicals and developing348
drugs. The ability to dissect the intercellular communication at the tissue-level in vitro offers the ability to examine349
how, for example, endocrine disrupting chemicals, may alter the gravid uterus and drive it towards a pathogenic state350
(19, 21). Akin to the ex vivo fetal membrane experimental models described above, an IFMOC will provide a “living”351
model of the fetal membrane, including tissue polarity, analysis of cell specific paracrine networks, and membrane352
barrier function (Figure 2). These functional quantitative and qualitative outcomes will facilitate our understanding353
of bacterial colonization and transmittance from the maternal side to the amnion. Although infections are a common354
causes of PTB, only a subset of women develop CAM-induced PTB, suggesting that other stressors are at play.355
356
We and others have observed that environmental toxicants may cause disruptions of immune-endocrine pathways357
during infection-related processes which may contribute to disease pathogenesis, although, human epidemiological358
data has been less conclusive (76-78). Animals models have shown that environmental toxicant exposures, such as359
endocrine disputing chemicals such as 2,3,7,8-tetrachlorodibenzodioxin (TCDD or dioxin) enhance the inflammatory360
response of pregnant dams resulting in a high incidence of spontaneous preterm birth in response to low level361
lipopolysaccharide (LPS) stimuli compared to vehicle treated controls (79, 80). The mechanisms behind this362
phenomenon remain elusive. An IFMOC may provide insight into the disparity between infectious stimuli and PTB363
by identify adverse outcome pathways from interacting toxicant and CAM pathogenic mechanisms.364
365
As mentioned, a key advantage of OoCs over current in vitro models include its microfluidic nature to maintain366
individualized chamber perfusion, aid in maintaining long-term cultures, reduce total culture volumes and introduce367
hemodynamic forces (e.g. shear stress) if desired. However, these microfluidic technologies also offer the possibility368
to interconnect different OoCs in tandem to mimic the systemic communication between organs. As an example, by369
interconnecting the IFMOC downstream of a liver organotypic model (e.g., liver-on-a-chip) it may provide a more370
15
robust physiologic response by modelling how xenobiotics pass through the liver, where they may be metabolized,371
prior to reaching the fetal membrane. These serial interactions between organs may continue to enhance the complexity372
of in vitro systems and provide innovative modelling avenues for reproductive research.373
374
Lastly, it is important to note that like any in vitro model, the OoCs do have intrinsic limitations in that they cannot375
fully reproduce all biological and physiological processes. In our first generation IFMOC, we focused on the376
macrophages as a representative immune cell that plays a critical role in both physiological and pathological processes377
of the fetal membrane. However, additional or alternative cell types, such as neutrophils or natural killer cells, can be378
incorporated within the platform to characterize their contribution to inflammatory processes in response to infections.379
Some technical limitations involve the properties of polydimethylsiloxane (PDMS), the prototypical material from380
which many of these devices are fabricated, including our first generation IFMOC. While PDMS serves as the gold381
standard for microfabrication as a biocompatible and air permeable substrate, its hydrophobic nature is prone to absorb382
lipophilic molecules (81, 82). This effect may hinder the immediate ability to perform detailed383
pharmacokinetic/pharmacodynamic (PK/PD) analysis of certain drugs; nonetheless these OoCs can provide an initial384
phenotypic screening tool until novel alternative materials become available. Lastly, the idealized IFMOC described385
herein focuses primarily on paracrine communication as a means of crosstalk between cells; however, we must386
consider that cell-cell contact and cell-ECM play a critical role to mediate tissue homeostasis. While these models387
may not be able to replicate all physiologic conditions that are found in vivo, OoCs are an innovative emerging388
technology with the promise of enhancing current human in vitro studies to generate more comprehensive389
understanding into tissue homeostasis and disease pathogenesis.390
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Figure Legends605
606
FIGURE 1. Chorioamnionitis and pregnancy complications. (A.) A simplified model of the pregnant uterus, with607
the fetal membranes (red) extending from the placenta and surrounding the developing fetus, which is suspended in608
amniotic fluid. (B.) Bacteria are drawn colonizing the vagina, ascending through the cervical canal, and invading the609
fetal membranes to provoke an inflammatory response (chorioamnionitis). Infection can spread to the fetus causing610
fetal inflammatory response syndrome (FIRS) or the placenta (placentitis). Complications of chorioamnionitis include611
preterm premature rupture of the fetal membranes (PPROM), preterm birth, stillbirth or neonatal sepsis.612
613
FIGURE 2. Histologic characterization of the fetal membrane structure. The fetal membrane is composed of614
representative layers that include the chorion (A.) primarily consisting of trophoblasts, the decidua (B.), and an615
amniotic epithelial monolayer (C.). Resident immune cells, including, macrophages (D.), structural mesenchymal cells616
and extracellular matrix make up the remainder of the microenvironment. The histologic dimensions of each617
component was approximated by analyzing at least four representative images (original magnification 20X) from six618
different 2mm punch biopsies of fetal membranes from human term non-laboring pregnancies using a protocol619
approved by the Vanderbilt University Institutional Review Board. Analysis includes standard deviation of the sample.620
Macrophages density assessed by measuring positive staining for CD68 by immunohistochemistry. For a621
representative of the total leukocyte distributions, please refer to (44).622
623
FIGURE 3. Conceptualization for an instrumented fetal membrane on a chip (IFMOC). Allosteric and functional624
scaling are critical facets of tissue modeling in order to incorporate the appropriate cell types at physiologic ratios.625
The idealized cellular microenvironment and tissue composition are summarized in (A.) as an aid to scale and develop626
innovative models of the fetal membrane.  (B.) A conceptualized schematic of an IFMOC may recapitulate the627
microfluidic scaling and compartmentalize the cellular composition of the fetal membrane in a multi-culture system.628
These models may provide insight into intercellular crosstalk and pathophysiology of CAM and PPROM.629
630
FIGURE 4. A prototype of the first generation IFMOC. (A.) Fetal membranes are primarily composed of amnion631
epithelial cells, chorion trophoblasts, residing leukocytes and decidual stromal cell. Our interest in macrophages stems632
21
from a sub-hypothesis to examine their role in inflammatory processes of the fetal membrane, but it is important to633
note, that any immune cell of interest can be incorporated within this system. (B.) A schematic of the development of634
the first generation IFMOC using a two-chamber microfluidic device for analysis of inflammatory networks and635
membrane barrier integrity. (C.) Immunofluorescent images of a compartmentalized co-culture of amnion epithelial636
cells and primary decidualized stromal cells. Scale bar represents 400 µm, unless otherwise noted.637
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